HWHG(SH:600079) Ge Long Hui A P P·2025-11-06 08:28Core Viewpoint - The company announced that its wholly-owned subsidiary has received approval for clinical trials of a new drug, HWH217 tablets, aimed at treating pulmonary arterial hypertension, a condition for which no similar compound has been approved in China [1] Company Summary - The drug HWH217 is classified as a Class 2.3 chemical drug containing known active ingredients and is intended for the treatment of Group 1 pulmonary arterial hypertension as defined by WHO [1] - The total research and development investment for this project has reached approximately 6 million yuan [1] Industry Summary - Currently, there are no approved compound formulations in China for the treatment of pulmonary arterial hypertension, indicating a potential market opportunity for HWH217 [1]